{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T15:45:55Z","timestamp":1780501555258,"version":"3.54.1"},"reference-count":8,"publisher":"The Pediatric Pharmacy Association","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024]]},"abstract":"<jats:p>The widespread use of highly effective cystic fibrosis transmembrane-conductance regulator \u00admodulator therapy has dramatically altered the lives of individuals with cystic fibrosis. Clinical trials leading to \u00admodulator approval by the US Food and Drug Administration demonstrated improvements in major \u00adoutcome measures including pulmonary function, gastrointestinal symptoms, and quality of life. Subsequent clinical experience has confirmed significant improvement across these domains. Adverse effects reported \u00adduring clinical trials included headache and dizziness amongst others including upper respiratory infections, abdominal pain, diarrhea, rash, and elevated serum transaminases. Post marketing clinical experience has suggested that there may be additional central nervous system adverse effects resulting from modulator therapy. Reported events after initiation of cystic fibrosis transmembrane-conductance regulator modulator treatment include headaches and increased prevalence of mental health concerns including anxiety and depression. We report a new tic disorder in a 7-year-old girl with cystic fibrosis treated with elexacaftor\/tezacaftor\/ivacaftor.<\/jats:p>","DOI":"10.5863\/1551-6776-29.1.82","type":"journal-article","created":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T12:02:14Z","timestamp":1707739334000},"page":"82-84","source":"Crossref","is-referenced-by-count":1,"title":["New Tic Disorder in a Child With Cystic Fibrosis Treated With Elexacaftor\/Tezacaftor\/Ivacaftor"],"prefix":"10.5863","volume":"29","author":[{"given":"Stephanie R.","family":"Duehlmeyer","sequence":"first","affiliation":[{"name":"Departments of Pharmacy (SRD, ECE) and Pediatrics (CMO) Children\u2019s Mercy - Kansas City, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Claire","family":"Elson","sequence":"additional","affiliation":[{"name":"Departments of Pharmacy (SRD, ECE) and Pediatrics (CMO) Children\u2019s Mercy - Kansas City, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher M.","family":"Oermann","sequence":"additional","affiliation":[{"name":"Departments of Pharmacy (SRD, ECE) and Pediatrics (CMO) Children\u2019s Mercy - Kansas City, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3883","reference":[{"issue":"2","key":"i2331-348X-29-1-82-b01","series-title":"Pediatr. Rev","first-page":"55","article-title":"Cystic fibrosis","volume":"42","author":"Dickinson","year":"2021","unstructured":"Dickinson\n              KM\n            , CollacoJM. Cystic fibrosis. Pediatr. Rev. 2021;42(2):55\u201367."},{"issue":"3","key":"i2331-348X-29-1-82-b02","series-title":"ANN Am Thorac Soc","first-page":"271","article-title":"Cystic fibrosis pulmonary guidelines: use of CFTR modulator therapy in patients with cystic fibrosis","volume":"15","author":"Ren","year":"2018","unstructured":"Ren\n              CL\n            , MorganRL, OermannC, \n          . Cystic fibrosis pulmonary guidelines: use of CFTR modulator therapy in patients with cystic fibrosis. ANN Am Thorac Soc. 2018;15(3):271\u2013280."},{"key":"i2331-348X-29-1-82-b03","series-title":"Eur Respir Rev","first-page":"200051","article-title":"Modulator treatment for people with cystic fibrosis: moving in the right direction","volume":"29","author":"Elborn","year":"2020","unstructured":"Elborn\n              JS\n            \n          . Modulator treatment for people with cystic fibrosis: moving in the right direction. Eur Respir Rev. 2020;29:200051."},{"key":"i2331-348X-29-1-82-b04","author":"Trikafta [package insert]","year":"2021","unstructured":"Trikafta [package insert]\n          . Boston, MA: Vertex Pharmaceuticals Incorporated; October2021."},{"issue":"6","key":"i2331-348X-29-1-82-b05","series-title":"J Cyst Fibros","first-page":"1061","article-title":"Dose adjustments of elexacaftor\/tezacaftor\/ivacaftor in response to mental health side effects in adults with cystic fibrosis","volume":"21","author":"Spoletini","year":"2022","unstructured":"Spoletini\n              G\n            , GillgrassL, PollardK, \n          . Dose adjustments of elexacaftor\/tezacaftor\/ivacaftor in response to mental health side effects in adults with cystic fibrosis. J Cyst Fibros. 2022;21(6):1061\u20131065."},{"key":"i2331-348X-29-1-82-b06","article-title":"Cystic Fibrosis Foundation Pharmacist and Pharmacy Technician E-mail List Serve","unstructured":"Cystic Fibrosis Foundation Pharmacist and Pharmacy Technician E-mail List Serve"},{"issue":"2","key":"i2331-348X-29-1-82-b07","series-title":"Clin Pharmacol Therapeutics","first-page":"239","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","unstructured":"Naranjo\n              CA\n            , BustoU, SellersEM, \n          . A method for estimating the probability of adverse drug reactionsClin Pharmacol Therapeutics1981;30(2):239\u2013245."},{"issue":"5","key":"i2331-348X-29-1-82-b08","series-title":"Chest","first-page":"1147","article-title":"Cystic fibrosis and the nervous system","volume":"151","author":"Reznikov","year":"2017","unstructured":"Reznikov\n              LR\n            \n          . Cystic fibrosis and the nervous system. Chest. 2017;151(5):1147\u20131155."}],"container-title":["The Journal of Pediatric Pharmacology and Therapeutics"],"original-title":[],"link":[{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/29\/1\/article-p82.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/meridian.allenpress.com\/jppt\/article-pdf\/29\/1\/82\/3325944\/i2331-348x-29-1-82.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jppt.kglmeridian.com\/downloadpdf\/journals\/jppt\/29\/1\/article-p82.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jppt.kglmeridian.com\/downloadpdf\/journals\/jppt\/29\/1\/article-p82.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:52:45Z","timestamp":1747356765000},"score":1,"resource":{"primary":{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/29\/1\/article-p82.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":8,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.5863\/1551-6776-29.1.82","relation":{},"ISSN":["2331-348X","1551-6776"],"issn-type":[{"value":"2331-348X","type":"electronic"},{"value":"1551-6776","type":"print"}],"subject":[],"published":{"date-parts":[[2024]]}}}